In this groundbreaking study, researchers developed a mucosal adenoviral-vector vaccine, ChAd-SARS-CoV-2-S, which demonstrated sustained and robust immunity against a challenging Omicron variant in nonhuman primates, indicating a promising direction for durable COVID-19 protection strategies. Unlike traditional intramuscular vaccines, this mucosal vaccine elicited a comprehensive immune response, potentially paving the way for more effective and long-lasting COVID-19 vaccines.
Regeneron’s $500M fund spotlights corporate venture’s influential role in biotech
When Regeneron announced a $500 million corporate venture capital fund last week, it was the first time in years that a storied large pharma had
April 23, 2024